利格列汀

Description

Linagliptin · CAS 668270-12-0 · C25H28N8O2. UNII 3X29ZEJ4R2. Melting Point: 190-196; Melting Point: 202 °C; Solubility: <1 mg/mL.

Identification

CAS Registry Number	668270-12-0
PubChem CID	10096344
Molecular formula	C25H28N8O2
IUPAC name	8-[(3R)-3-aminopiperidin-1-yl]-7-but-2-ynyl-3-methyl-1-[(4-methylquinazolin-2-yl)methyl]purine-2,6-dione
UNII (FDA)	3X29ZEJ4R2

Computed Descriptors

Molecular Weight	472.5
XLogP3	1.9
Hydrogen Bond Donor Count	1
Hydrogen Bond Acceptor Count	7
Rotatable Bond Count	4
Exact Mass	472.23352217
Monoisotopic Mass	472.23352217
Topological Polar Surface Area	113
Heavy Atom Count	35
Formal Charge	0

Physical & Chemical Properties

Melting Point	190-196
Melting Point	202 °C
Solubility	<1 mg/mL
Dissociation Constants	pKa1 = 1.9; pKa2 = 8.6

Physical description & handling notes

• White to yellow solid; also reported as a crystalline solid
• Soluble in methanol; sparingly soluble in ethanol; very slightly soluble in isopropanol, alcohol
• Stable if stored as directed; avoid strong oxidizing agents
• Thermal decomposition may produce toxic gases such as carbon monoxide, carbon dioxide, and nitrogen oxides.
• Slightly hygroscopic
• A 5mg oral dose of linagliptin results in >80% inhibition of dipeptidyl peptidase 4 (DPP-4) for ≥24 hours. Inhibition of DPP-4 increases the concentration of glucagon-like peptide 1 (GLP-1), leading to decreased glycosylated hemoglobin and fasting plasma glucose.

Documented Uses

• Linagliptin is indicated for the treatment of type II diabetes in addition to diet and exercise. It should not be used to treat type I diabetes or in diabetic ketoacidosis. An extended-release combination product containing empagliflozin, linagliptin, and metformin was approved by the FDA in January 2020 for the improvement of glycemic control in adults with type 2 diabetes mellitus when used adjunctively with diet and exercise.
• Linagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor which is used in combination with diet and exercise in the therapy of type 2 diabetes, either alone or in combination with other oral hypoglycemic agents. Linagliptin has been linked to rare instances of clinically apparent liver injury.
• Breast Feeding; Lactation; Milk, Human; Hypoglycemic Agents; Incretins; Dipeptidyl-Peptidase IV Inhibitors; DPP-4 Inhibitors
• Linagliptin; METformin Hydrochloride
• Tradjenta tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. /Included in US product label/
• There have been postmarketing reports of acute pancreatitis, including fatal pancreatitis, in patients taking Tradjenta. Take careful notice of potential signs and symptoms of pancreatitis. If pancreatitis is suspected, promptly discontinue Tradjenta and initiate appropriate management. It is unknown whether patients with a history of pancreatitis are at increased risk for the development of pancreatitis while using Tradjenta.

Synonyms

Linagliptin; 668270-12-0; Tradjenta; BI-1356; BI 1356; Trazenta; Trajenta; BI-1356-BS; linagliptine; Linagliptina; BS 1356 BS; BI1356; 3X29ZEJ4R2; BI-1356BS; BI 1356 BS; BS-1356-BS

Frequently Asked Questions

What are the CAS number and molecular formula of Linagliptin?

CAS 668270-12-0; molecular formula C25H28N8O2; molecular weight — g/mol.

What other names is Linagliptin known by?

Linagliptin, 668270-12-0, Tradjenta, BI-1356, BI 1356, Trazenta.

What are the key physical properties of Linagliptin?

Melting Point: 190-196; Melting Point: 202 °C; Solubility: <1 mg/mL; Dissociation Constants: pKa1 = 1.9; pKa2 = 8.6.

Facts on this page are taken from PubChem (US National Library of Medicine) and Wikidata. Grade-specific data — assay, moisture, particle size, packaging, shelf life — is issued per batch on the COA and is not published here.